研究者業績

基本情報

所属
藤田医科大学 医学部 医学科 呼吸器内科学Ⅰ 講師
学位
博士(医学)

J-GLOBAL ID
201501000782475831
researchmap会員ID
7000012733

論文

 8
  • Yuki Mieno, Masamichi Hayashi, Hiroki Sakakibara, Hiroshi Takahashi, Shiho Fujita, Sumito Isogai, Yasuhiro Goto, Sakurako Uozu, Mitsushi Okazawa, Kazuyoshi Imaizumi
    Internal medicine (Tokyo, Japan) 57(15) 2157-2163 2018年8月1日  査読有り
    Objective Sleep apnea syndrome is more prevalent among men than women and is frequently accompanied by metabolic syndrome (MetS). However, gender differences in the effect of sleep-disordered breathing (SDB) leading to the risk of MetS remain unclear. The aim of our study was to investigate the clinical characteristics of SDB in women and the differential influence of SDB on MetS between genders. Methods In a single-center retrospective study, we compared the data of 1,809 consecutive SDB patients by gender to clarify the characteristics of sleep disorders in women. We also compared the prevalence of MetS and its related abnormalities by gender. A logistic regression analysis was used to determine the contributory factors for MetS. Results The mean age and proportion of patients over 50 years of age were higher in women than in men. SDB was milder in women than in men according to polysomnography findings. Elevated Hemoglobin A1c levels and hyperlipidemia were less frequent in women than in men. The MetS prevalence was similar in women and men (30.0% vs. 35.2%). A logistic regression analysis showed that the apnea-hypopnea index (AHI) was an independent risk factor for MetS in both genders, but that female gender was independently associated with a decreased prevalence of MetS and its related abnormalities. Conclusion Female SDB patients tend to be older with milder apnea and sleepiness than male SDB patients. A higher AHI is a significant risk factor for MetS in both genders, although female gender is an independent inhibitory factor for developing MetS in SDB patients.
  • Sumito Isogai, Yoshikazu Niwa, Hiroshi Yatsuya, Masamichi Hayashi, Naoki Yamamoto, Takuya Okamura, Tomoyuki Minezawa, Yasuhiro Goto, Teppei Yamaguchi, Tomoko Takeyama, Yosuke Sakakibara, Sayako Morikawa, Tomoya Horiguchi, Yusuke Gotoh, Yuki Mieno, Sakurako Uozu, Toru Nakanishi, Mitsushi Okazawa, Hiroki Sakakibara, Kazuyoshi Imaizumi
    ALLERGOLOGY INTERNATIONAL 66(2) 360-362 2017年4月  査読有り
  • Morikawa S, Okamura T, Minezawa T, Goto Y, Hayashi M, Yamaguchi T, Isogai S, Mieno Y, Yamamoto N, Uozu S, Nakanishi T, Okazawa M, Imaizumi K
    Therapeutic advances in respiratory disease 10(6) 518-524 2016年12月  査読有り
  • Tomoyuki Minezawa, Takuya Okamura, Hiroshi Yatsuya, Naoki Yamamoto, Sayako Morikawa, Teppei Yamaguchi, Mariko Morishita, Yoshikazu Niwa, Tomoko Takeyama, Yuki Mieno, Tami Hoshino, Sakurako Uozu, Yasuhiro Goto, Masamichi Hayashi, Sumito Isogai, Masaki Matsuo, Toru Nakanishi, Naozumi Hashimoto, Mitsushi Okazawa, Kazuyoshi Imaizumi
    BMC MEDICAL IMAGING 15 21 2015年6月  査読有り
    Background: Recent advances in bronchoscopy, such as transbronchial biopsy (TBB) using endobronchial ultrasonography with a guide sheath (EBUS-GS), have improved the diagnostic yield of small-sized peripheral lung lesions. In some cases, however, it is difficult to obtain adequate biopsy samples for pathological diagnosis. Adequate prediction of the diagnostic accuracy of TBB with EBUS-GS is important before deciding whether bronchoscopy should be performed. Methods: We retrospectively reviewed 149 consecutive patients who underwent TBB with EBUS-GS for small-sized peripheral lung lesions (<= 30 mm in diameter) from April 2012 to March 2013. We conducted an exploratory analysis to identify clinical factors that can predict an accurate diagnosis by TBB with EBUS-GS. All patients underwent thin-section chest computed tomography (CT) scans (0.5-mm slices), and the CT bronchus sign was evaluated before bronchoscopy in a group discussion. The final diagnoses were pathologically or clinically confirmed in all studied patients (malignant lesions, 110 patients; benign lesions, 39 patients). Results: The total diagnostic yield in this study was 72.5 % (95 % confidence interval: 64.8-79.0 %). Lesion size, lesion visibility on chest X-ray, and classification of the CT bronchus sign were factors significantly associated with the definitive biopsy result in the univariate analysis. In the multivariate analysis, only the CT bronchus sign remained as a significant predictive factor for successful bronchoscopic diagnosis. The CT bronchus sign was also significantly associated with the EBUS findings of the lesions. Conclusion: Our results suggest that the CT bronchus sign is a powerful predictive factor for successful TBB with EBUS-GS.
  • Teppei Yamaguchi, Sumito Isogai, Takuya Okamura, Sakurako Uozu, Yuki Mieno, Tami Hoshino, Yasuhiro Goto, Masamichi Hayashi, Toru Nakanishi, Kazuyoshi Imaizumi
    Case Reports in Oncology 8(1) 78-82 2015年5月22日  査読有り
    A 72-year-old man undergoing continuous ambulatory peritoneal dialysis (CAPD) for chronic renal failure and who had undergone right upper lobectomy for lung adenocarcinoma (pT2aN0M0) 2 years ago was admitted for recurrence of lung cancer presenting as multiple brain metastases. An epidermal growth factor receptor mutation analysis of his lung cancer revealed a deletion of 15 nucleotides (E746-A750) in exon 19. After whole-brain radiotherapy, we started daily administration of 250 mg gefitinib under the continuation of CAPD and performed a pharmacokinetic analysis. We speculated that the plasma concentration of gefitinib reached the steady state at least by day 16 after the start of gefitinib (626.6 ng/ml at trough level). On day 46, the plasma concentration was 538.4 ng/ml at trough level and the concentration in the peritoneal dialysis fluid was 34.6 ng/ml, suggesting that CAPD appeared to have little effect on the pharmacokinetics of gefitinib. During gefitinib therapy, there were no significant adverse events except for grade 2 diarrhea. Gefitinib could be safely administered to a patient undergoing CAPD.

MISC

 10
  • Kan Sano, Eiichi Watanabe, Junichiro Hayano, Yuuki Mieno, Yoshihiro Sobue, Mayumi Yamamoto, Tomohide Ichikawa, Hiroki Sakakibara, Kazuyoshi Imaizumi, Yukio Ozaki
    European journal of heart failure 15(9) 1003-10 2013年9月  査読有り
    AIMS: We examined whether the severity of central sleep apnoea (CSA) and the level of C-reactive protein are associated with the prevalence and complexity of arrhythmias, and whether these factors contribute to increased risk of nocturnal sudden death. METHODS AND RESULTS: We prospectively examined 178 patients (age 70 ± 1 years) who were admitted to our hospital due to worsening heart failure. We recorded a simultaneous overnight cardiorespiratory polygraph and Holter ECG. Obstructive sleep apnoea was excluded and patients were dichotomized based on the median value of the central apnoea index (CAI) of 7.5/h. The prevalence and complexity of arrhythmias were compared between daytime (06:00 h to 15:00 h) and night-time (21:00 h to 06:00 h). A multivariate logistic regression analysis revealed that the CAI was associated with prevalence of atrial fibrillation (AF) [odds ratio 1.03, 95% confidence interval (CI) 1.02-2.51)] and sinus pause during the night-time period (1.12, 95% CI 1.08-1.35). The CAI and C-reactive protein were independently associated with non-sustained ventricular tachycardia during both daytime (1.22, 95% CI 1.00-6.92; and 5.82, 2.58-56.1, respectively) and night-time periods (3.57, 95% CI 1.06-13.1; and 10.7, 3.30-44.4, respectively). During a mean follow-up period of 22 months, 30 (17%) patients had cardiovascular deaths and the CSA was an independent predictor (hazard ratio 1.29, 95% CI 1.16-2.32); only 5 (2.8%) of them died due to ventricular tachyarrhythmia, occurring during wakefulness. CONCLUSIONS: We demonstrated that the severity of CSA and C-reactive protein levels are independently associated with the prevalence and complexity of arrhythmias. CSA was associated with increased mortality risk, but it was not related directly to nocturnal death due to ventricular tachyarrhythmia.
  • Hideyasu Shimizu, Masamichi Hayashi, Yuji Saito, Yuki Mieno, Yasuo Takeuchi, Fumihiko Sasaki, Hiroki Sakakibara, Kensei Naito, Mitsushi Okazawa
    Cough 9(1) 4 2013年2月7日  査読有り
    Background: Chronic cough is one of the most challenging symptoms to diagnose and treat, not only because of the variety of underlying disorders but also its varying susceptibility to treatments. Etiological studies of chronic cough vary depending on the clinical settings and the particular interests of investigators.Objectives: The purposes of this study were first to categorize the etiology of chronic cough by its response to systematic diagnostic treatments starting from the β2 agonist and second to sub-categorize β2 agonist responsive cough (BRC) by the airway hyperresponsiveness.Methods: One hundred and eighty-four never-smokers received the maximal dose of procaterol to diagnose BRC. BRC was sub-categorized into two groups with or without airway hyperresponsiveness measured by the methacholine challenge test. Sinobronchial syndrome (SBS) was diagnosed by postnasal drip symptoms and by the response to clarythromycin and carbocysteine. Atopic cough (AC) was diagnosed by the evidence of atopy and the response to cetirizine hydrochloride. Gastroesophageal reflux disease (GERD) was diagnosed by the response to rabeprazole sodium. Since we did not investigate eosinophil counts in the tissue or in the induced sputum, no diagnosis of eosinophilic bronchitis was made.Results: One hundred and nine patients had BRC. Twenty-three of them had bronchial asthma (BA), 53 had cough variant asthma (CVA) and 33 had non-hyperresponsive BRC (NHBRC). Thirty-one patients had GERD, 27 had AC and 14 had SBS. Twenty-five patients had more than one diagnosis in combination, while 6 had other miscellaneous diseases. Twelve patients were undiagnosed and 11 dropped out of the study.Conclusions: The majority of chronic cough was BRC. NHBRC was a new chronic cough entity. GERD is a common cause of chronic cough in Japan, as in Western countries. AC and SBS are also causes of chronic cough in Japan.Trial registration: University hospital medical information network (UMIN 000007483). © 2013 Shimizu et al. licensee BioMed Central Ltd.
  • 三重野ゆうき
    学位論文集 321-338 2013年  
  • 榊原博樹, 林 正道, 三重野ゆうき, 佐々木文彦
    平成23年度研究報告書、厚生労働科学研究費・循環器疾患・糖尿病等生活習慣病対策総合研究事業 101-108 2012年  
  • 榊原博樹, 井水ひろみ, 三重野ゆうき, 林 正道, 多田利彦, 齊藤雄二, 佐々木文彦, 平田正敏, 吉川充史, 藤田志保, 今村基尊
    分担研究報告書、睡眠時無呼吸症候群関連ガイドラインの検証、厚生労働省精神・神経疾患研究. 平成20年度?平成22年度総括研究報告書 67-72 2011年  
  • 榊原博樹, 齊藤雄二, 磯谷澄都, 三重野ゆうき
    平成22年度総括・分担研究報告書,厚生労働科学研究・免疫アレルギー疾患等予防・治療研究事業 21-24 2011年  
  • 磯谷澄都, 多田利彦, 三重野ゆうき, 井水ひろみ, 小橋保夫, 加藤 敦, 米田有希子, 清水秀康, 星野多美, 内山康裕, 竹内保雄, 戸谷嘉孝, 齊藤雄二, 佐々木文彦, 岡澤光芝, 榊原博樹
    日本職業・環境アレルギー学会雑誌 17(2) 17-22 2010年  
  • 榊原博樹, 井水ひろみ, 三重野ゆうき, 林 正道, 齊藤雄二, 平田正敏, 吉川充史, 藤田志保
    平成21年度研究報告書別冊、厚生労働科学研究・難治性疾患克服研究事業 280-284 2010年  
  • Yoshitaka Totani, Yuji Saito, Masamichi Hayashi, Toshihiko Tada, Yasuo Kohashi, Yuki Mieno, Atsushi Kato, Hiromi Imizu, Yukiko Yoneda, Tami Hoshino, Yasuhiro Uchiyama, Yasuo Takeuchi, Mitsushi Okazawa, Hiroki Sakakibara
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 64(6) 1181-1185 2009年11月  査読有り
    To assess the efficacy and toxicity of an oral anticancer fluoropyrimidine derivative, S-1, for previously treated patients with advanced non-small cell lung cancer (NSCLC). Patients with advanced (clinical stage IIIB-IV) NSCLC who had previously received one platinum-based chemotherapy were enrolled. S-1 was administered orally at the dosage decided by using the nomogram based on patient BSA b.i.d. for 28 consecutive days, repeated every 6 weeks. Between August 2005 and July 2007, 50 patients were entered into this study. Six patients achieved partial response (PR), and the overall response rate of eligible patients was 12.5% (6/48) (95% confidence interval (95%CI), 3.1-21.9%). Disease control rate was 39.6% (19/48) (95%CI, 25.7-53.4%). Median progression-free survival was 2.5 months. Median survival time was 8.2 months, and 1-year survival rate was 29.6%. No grade 4 toxicities were encountered. Grade 3 hematological toxicities comprised neutropenia in one patient (2.1%) and anemia in one patient (2.1%). Grade 3 non-hematological toxicities were observed in only five patients (10.4%). Treatment-related death did not occur. S-1 is an active and well-tolerated monotherapy for second-line treatment of advanced NSCLC.
  • 榊原博樹, 井水ひろみ, 三重野ゆうき, 内山康裕, 林 正道, 齊藤雄二, 佐々木文彦, 平田正敏, 吉川充史, 藤田志保
    平成20年度研究報告書 252-262 2009年  

書籍等出版物

 4

講演・口頭発表等

 70